Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
Top Cited Papers
- 1 May 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (13), 1474-1494
- https://doi.org/10.1200/jco.19.02768
Abstract
This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging. An ASCO multidisciplinary Expert Panel, with representatives from the European Association of Urology, American Urological Association, and the College of American Pathologists, conducted a systematic literature review of localized prostate cancer biomarker studies between January 2013 and January 2019. Numerous tissue-based molecular biomarkers were evaluated for their prognostic capabilities and potential for improving management decisions. Here, the Panel makes recommendations regarding the clinical use and indications of these biomarkers. Of 555 studies identified, 77 were selected for inclusion plus 32 additional references selected by the Expert Panel. Few biomarkers had rigorous testing involving multiple cohorts and only 5 of these tests are commercially available currently: Oncotype Dx Prostate, Prolaris, Decipher, Decipher PORTOS, and ProMark. With various degrees of value and validation, multiple biomarkers have been shown to refine risk stratification and can be considered for select men to improve management decisions. There is a paucity of prospective studies assessing short- and long-term outcomes of patients when these markers are integrated into clinical decision making. Tissue-based molecular biomarkers (evaluating the sample with the highest volume of the highest Gleason pattern) may improve risk stratification when added to standard clinical parameters, but the Expert Panel endorses their use only in situations in which the assay results, when considered as a whole with routine clinical factors, are likely to affect a clinical decision. These assays are not recommended for routine use as they have not been prospectively tested or shown to improve long-term outcomes—for example, quality of life, need for treatment, or survival. Additional information is available at www.asco.org/genitourinary-cancer-guidelines.This publication has 160 references indexed in Scilit:
- Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical ProstatectomyPLOS ONE, 2013
- Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsiesBMC Genomics, 2013
- Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohortBritish Journal of Cancer, 2012
- Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementabilityJournal of the American Medical Informatics Association, 2012
- Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic PrescriptionsJournal of Oncology Practice, 2011
- Gait Speed and Survival in Older AdultsJAMA, 2011
- Correlates of Psychological Distress and Major Depressive Disorder Among African American MenResearch on Social Work Practice, 2010
- American Society of Clinical Oncology Guidance Statement: The Cost of Cancer CareJournal of Clinical Oncology, 2009
- Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical TrialJournal of Urology, 2009
- Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical ProstatectomyJNCI Journal of the National Cancer Institute, 2006